Immune cell therapy for advanced heart failure from blocked arteries
Treatments studied
Part of Heart & circulation clinical trials.
This early-phase study tests a new type of immune cell therapy (CAR-DC) for people with advanced heart failure due to blocked arteries. It aims to see if the treatment is safe and may help improve heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your heart failure is caused by blocked arteries and you have a very weak heart pump (ejection fraction below 35%).
- You have been on the best available heart medicines for at least 3 months.
- You have not had a recent heart procedure (like stent, bypass, or pacemaker) in the past 3 months, and you do not plan one.
- You do not have other serious health issues like active cancer, kidney failure on dialysis, or a major infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (FAP iCDC) for people who have had a severe heart attack that caused their heart to pump too weakly (cardiogenic shock). The goal is to see if this treatment can help the heart recover better after the artery has been opened.
This trial tests a second dose of specialized immune cells (called CAR-DC) in patients with severe dilated cardiomyopathy (a weakened heart muscle) who received one dose before but saw their heart function decline back to baseline. The goal is to see if a second dose is safe and can improve heart function when the first treatment's benefits wore off.
This trial tests a new treatment called FAP iCDC for people with end-stage dilated cardiomyopathy, a type of heart muscle disease. It aims to see if this therapy is safe and helps improve heart function when standard medicines are no longer enough.
This trial tests a new treatment using heart muscle cells made from stem cells (iPSC-CMs) combined with either a heart pump (LVAD) or bypass surgery (CABG) for people with end-stage heart failure. The goal is to see if adding these cells can help the heart work better.
This early-stage study tests an experimental treatment that uses engineered immune cells (called CAR natural killer cells) to calm overactive immune responses in people with moderate to severe autoimmune diseases that have not fully responded to standard treatments. It aims to offer a new option for patients who have not gotten enough benefit from usual therapies.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Hear when a new Ischemic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.